Breaking Finance News

Leerink Partners announced Alexion Pharma (NASDAQ:ALXN), bumping up its stock price target to $182.00 today

In a report released on 9/13/2017 Leerink Partners increased the stock price target of Alexion Pharma (NASDAQ:ALXN) from $170.00 to $182.00 reporting a possible upside of 0.26%.

Just yesterday Alexion Pharma (NASDAQ:ALXN) traded 0.05% higher at $144.07. Alexion Pharma’s 50-day moving average is $137.20 and its 200-day moving average is $124.25. The last closing price is up 16.01% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 283,478 shares of ALXN traded hands, down from an average trading volume of 2,140,180

Recent Performance Chart

Alexion Pharma (NASDAQ:ALXN)

Alexion Pharma has price-earnings ratio of 62.51 with a one year low of $96.18 and a one year high of $149.34 and has a total market value of $0.

A total of 18 analysts have released a research note on Alexion Pharma. Seven analysts rating the company a strong buy, six analysts rating the company a buy, seven analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $187.61.

More About Alexion Pharma (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.